Baseline characteristics
DISEASE, PGA
One hundred and thirteen patients who had inadequate responses to MTX (MTX-IR) with or without bDMARDs were enrolled in this study. The overall design, including patient inclusion and exclusion criteria of the study, was described in Baseline demographic and clinical characteristics of the included patientsData reported as mean (SD).CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28 Joint; EGA, Evaluator’s Global Assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, Patient’s Global Assessment.